This is a material regulatory milestone for a micro-cap biotech with minimal liquidity. The strong subgroup data and Breakthrough designation increase the odds of accelerated approval. Traders should monitor for the FDA meeting outcome and any guidance on a potential Biologics License Application (BLA) submission. Positive feedback could drive significant upside given the company's small $13M market cap.
Price Chart
Executive Summary
BioCardia submitted clinical data from its CardiAMP HF trial to the FDA and plans to meet with the agency this quarter to discuss an accelerated approval pathway for its CardiAMP System in ischemic chronic heart failure patients with elevated biomarkers. The company highlighted a 47% relative risk reduction in all-cause cardiac death and 37% reduction in non-fatal major adverse cardiac events in a high-risk subgroup, supporting its Breakthrough Therapy designation.
Key Facts
- BioCardia submitted CardiAMP HF clinical study data to the FDA and requested a meeting to discuss accelerated approval.
- The FDA meeting is expected this quarter and will be conducted under the company's existing Breakthrough Therapy designation.
- In a subgroup of ischemic HFrEF patients with elevated heart stress biomarkers, treatment showed a 47% relative risk reduction in all-cause cardiac death and 37% reduction in non-fatal MACE.
- Quality of life improvements were statistically significant (p=0.04) in the biomarker-positive subgroup.
- The CardiAMP System uses autologous bone marrow cells delivered via catheter to treat microvascular dysfunction in heart failure.
Financial Impact
Potential near-term regulatory catalyst with high strategic value; no direct revenue impact yet but approval could open commercial pathway
Risk Factors
- FDA may not accept accelerated approval based on subgroup data alone.
- Company has limited cash resources and may need to raise capital, risking dilution.
- Subgroup results, while promising, are not from a randomized controlled trial endpoint.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267485 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers